| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8535717 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(2 years from now) | |
| US8425938 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(2 years from now) | |
| US8163306 | TRIPOINT | Oral drug delivery system |
Sep, 2027
(3 years from now) | |
| US8431156 | TRIPOINT | Pharmaceutical composition |
Oct, 2027
(4 years from now) | |
| US8470367 | TRIPOINT | Oral drug delivery system |
Oct, 2027
(4 years from now) | |
Elepsia Xr is owned by Tripoint.
Elepsia Xr contains Levetiracetam.
Elepsia Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Elepsia Xr was authorised for market use on 20 December, 2018.
Elepsia Xr is available in tablet, extended release;oral dosage forms.
The generics of Elepsia Xr are possible to be released after 31 October, 2027.
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ELEPSIA XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic